Outrun Therapeutics Ltd.

https://www.outruntx.com

Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 ligase inhibition to maintain levels of critical proteins that are otherwise destabilised in certain diseases, disrupting the body’s highly sophisticated natural disease suppression processes. Blocking E3 ligase activity enables protein stabilisation “at source” compared to other approaches. It is directly part of the tagging mechanism used by healthy cells to destabilise proteins that are dispensable or mis-formed. Protein stabilisation could be applicable to a wide range of indications, including oncology and neurology. Despite the very high interest in E3 ligases as a therapeutic target, they have been challenging to drug. This is a roadblock that Outrun is addressing through its world class knowledge of E3 ligase biology and its proprietary discovery platform, which simplifies and dramatically scales the assessment of E3 ligase targets, thereby significantly reducing discovery time. Furthermore, the platform’s elegant engineered protein sensor (EPS) screen is enabling Outrun to build a pipeline of highly valuable, small molecule, first-in-class, E3 ligase inhibitors to prevent protein degradation, as well as identify novel E3 ligase targets involved in a range of diseases. Outrun’s lead programme is a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours. Spun out of founder Prof. Satpal Virdee’s lab at the world-renowned MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, Outrun is led by a seasoned management team with a strong track record in creating robust biopharma businesses. It is backed by M Ventures and MP Healthcare Venture Management. *

	Start	2019-11-26 established (s-off)
	Predecessor	University of Dundee
	Industry	protein stabilisation technology
	Industry 2	E3 ligase inhibitor
	Person	Porter, Carolyn (Outrun Therapeutics 202401– CEO before CytoSeek + OxStem + Univ Oxford/Isis Innovation + Novartis)

	Region	Dundee
	Country	United Kingdom (GB)
	Street	Errol Road Invergowrie
	City	DD2 5DA Dundee
		Address record changed: 2024-06-13

Basic data	Employees	n. a.

		* Document for »About Section«: Outrun Therapeutics Ltd.. (4/18/24). "Press Release: Outrun Therapeutics Launches with a $10m Seed Financing from M Ventures and MP Healthcare Venture Management to Develop a Protein Stabilisation Pipeline". Dundee.

		Record changed: 2024-06-13